Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84).
Article Details
- CitationCopy to clipboard
Haslam IS, Jones K, Coleman T, Simmons NL
Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84).
Biochem Pharmacol. 2008 Oct 1;76(7):850-61. doi: 10.1016/j.bcp.2008.07.020. Epub 2008 Jul 23.
- PubMed ID
- 18703021 [ View in PubMed]
- Abstract
Intestinal induction of Pgp is known to limit the oral availability of certain drug compounds and give rise to detrimental drug-drug interactions. We have investigated the induction of P-glycoprotein (Pgp; MDR1) activity in a human intestinal epithelial cell line (T84) following pre-exposure to a panel of drug compounds, reported to be Pgp substrates, inhibitors or inducers. Human MDR1-transfected MDCKII epithelial monolayers were used to assess Pgp substrate interactions and inhibition of digoxin secretion by the selected drug compounds. The T84 cell line was used to assess induction of Pgp-mediated digoxin secretion following pre-exposure to the same compounds. Changes in gene expression (MDR1, MRP2, PXR and CAR) were determined by quantitative RT-PCR. Net transepithelial digoxin secretion was increased (1.3 fold, n=6, P<0.05) following pre-exposure to the PXR activator hyperforin (100nM, 72h), as was MDR1 mRNA expression (3.0 fold, n=4, P<0.05). A number of Pgp substrates (quinidine, amprenavir, irinotecan, topotecan, atorvastatin and erythromycin) induced net digoxin secretion, as did the non-Pgp substrate artemisinin. Various non-Pgp substrates demonstrated inhibition of digoxin secretion (verapamil, mifepristone, clotrimazole, mevastatin, diltiazem and isradipine) but did not induce Pgp-mediated digoxin secretion. Of the compounds that increased Pgp secretion, quinidine, topotecan, atorvastatin and amprenavir pre-exposure also elevated MDR1 mRNA levels, whereas erythromycin, irinotecan and artemisinin displayed no change in transcript levels. This indicates possible post-translational regulation of digoxin secretion. Finally, a strong correlation between drug modulation of MRP2 and PXR mRNA expression levels was evident.
DrugBank Data that Cites this Article
- Drug Transporters
Drug Transporter Kind Organism Pharmacological Action Actions Digoxin P-glycoprotein 1 Protein Humans UnknownSubstrateInhibitorInducerDetails - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareDigoxinLevothyroxine Levothyroxine may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy. DigoxinPrednisolone phosphate Prednisolone phosphate may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy. DigoxinDexamethasone acetate Dexamethasone acetate may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy. DigoxinLorlatinib Lorlatinib may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.